AURA

Several events have impacted Aura Biosciences, Inc. (AURA) stock price in the past six months. Aura Biosciences announced and closed a public offering of common stock and pre-funded warrants, raising $299 million but resulting in material dilution. Natalie Holles was appointed as President and a member of the Board of Directors, succeeding Elisabet de los Pinos. Aura Biosciences reported its fourth quarter and full year 2025 financial results, with an EPS of -$0.37, beating expectations, and provided updates on the CoMpass and NMIBC trials. The company reported its third quarter 2025 financial results, updating guidance for the CoMpass trial and presenting immune profiling data for bel-sar in bladder cancer. Insider Elisabet de los Pinos sold 47,648 shares of the company's stock. Aura Biosciences' stock has increased by 53.5% since the start of 2026, reaching a new 52-week high of $9.54 in early May 2026.